Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
The Pharma Data
JUNE 2, 2022
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 Chief Medical Officer of Myovant Sciences, Inc. “We NYSE: PFE) announced today that the U.S.
52 
Let's personalize your content